Avalyn Pharma Inc.(AVLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AVLN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Avalyn Pharma Inc. (AVLN), a Healthcare sector company. AVLN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Avalyn Pharma Inc. reports net income of $-26.9M, free cash flow of $-30.2M. AVLN trades on the Nasdaq exchange and files with the SEC under CIK 1540171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalyn Pharma Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-26.9M
Free Cash Flow
Q1 2026
$-30.2M
AI Insight: AVLN Financial Trends
Pre-revenue biotech burning cash with negative equity; clinical-stage company requires capital raise or liquidity event.
• No revenue reported in Q1 2026; operating loss of $28M with negative $30M operating cash flow.
• Stockholders' equity is negative at $-264M, indicating liabilities exceed assets substantially.
⚠ Burn rate of ~$30M/quarter from operations; runway viability depends on funding announcements or clinical milestones.
AI Insight: AVLN Ratio Trends
Avalyn Pharma shows only one measurable metric in Q1 2026: deeply negative ROA of -79.2%, indicating severe near-term losses.
• ROA of -79.2% in Q1 2026 reflects substantial quarterly net losses relative to total assets.
⚠ Operating margin, NPM, ROE, ROIC, and leverage all absent from Q1 2026 data—insufficient visibility into profitability and capital efficiency.
Get alerted when AVLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Avalyn Pharma Inc. including:
More Healthcare Companies
View all Healthcare →Put AVLN on your watchlist
Track score changes the day Avalyn Pharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVLN a good stock to buy?
13F Pro's AI-powered analysis of Avalyn Pharma Inc. (AVLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVLN are available on the AVLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AVLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avalyn Pharma Inc.'s investment landscape.